{"id":"trivalent-influenza-vaccine-b","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site soreness or erythema"},{"rate":"5–15","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated or attenuated influenza virus antigens that trigger both humoral and cellular immune responses. Upon vaccination, B cells produce strain-specific antibodies that neutralize circulating influenza viruses, while T cells provide additional immune memory. This prevents infection or reduces disease severity when vaccinated individuals encounter wild-type influenza.","oneSentence":"This trivalent influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus (typically two A strains and one B strain).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:10.835Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT07192458","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-09-17","conditions":"Immunization; Infection|Transplantation Infection|Influenza, Influenza","enrollment":60},{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT06291857","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-12-09","conditions":"COVID-19","enrollment":9320},{"nctId":"NCT06485752","phase":"PHASE2, PHASE3","title":"Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine","status":"WITHDRAWN","sponsor":"Novavax","startDate":"2024-11","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04080531","phase":"PHASE4","title":"Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-10-18","conditions":"Plasma Cell Neoplasm","enrollment":165},{"nctId":"NCT03927131","phase":"PHASE3","title":"Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-12","conditions":"Influenza, Human","enrollment":5822},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT03849560","phase":"PHASE2, PHASE3","title":"Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2016-11","conditions":"Influenza","enrollment":612},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT03744104","phase":"PHASE3","title":"A Clinical Trial of A Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-10-11","conditions":"Influenza","enrollment":2688},{"nctId":"NCT04363359","phase":"PHASE2","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-01-15","conditions":"Influenza","enrollment":1980},{"nctId":"NCT02385123","phase":"PHASE4","title":"Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-04-01","conditions":"Influenza, Influenza Immunisation","enrollment":60},{"nctId":"NCT02485639","phase":"PHASE4","title":"Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-23","conditions":"Influenza, Influenza Immunisation","enrollment":27},{"nctId":"NCT02677493","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-10","conditions":"Influenza","enrollment":1794},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":"Influenza","enrollment":864},{"nctId":"NCT04484532","phase":"EARLY_PHASE1","title":"Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-10-17","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":130},{"nctId":"NCT03293498","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)","status":"COMPLETED","sponsor":"Novavax","startDate":"2017-09-18","conditions":"Influenza","enrollment":330},{"nctId":"NCT03658629","phase":"PHASE2","title":"Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults","status":"TERMINATED","sponsor":"Novavax","startDate":"2018-09-24","conditions":"Influenza, Human","enrollment":1375},{"nctId":"NCT03438487","phase":"","title":"Flucelvax (TIVc or QIVc) Pregnancy Registry","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-09-01","conditions":"Influenza, Human, Pregnancy, Birth Defect","enrollment":692},{"nctId":"NCT01676402","phase":"PHASE1","title":"Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-08","conditions":"Influenza","enrollment":316},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT03282240","phase":"PHASE3","title":"Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-09-08","conditions":"Influenza","enrollment":2670},{"nctId":"NCT04833101","phase":"PHASE4","title":"Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-04-07","conditions":"COVID-19","enrollment":120},{"nctId":"NCT00539981","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09-15","conditions":"Influenza","enrollment":4648},{"nctId":"NCT02747407","phase":"","title":"Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-05","conditions":"Astrocytoma, Glioma, Oligodendroglioma","enrollment":55},{"nctId":"NCT00192192","phase":"PHASE3","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2000-11","conditions":"Influenza","enrollment":20},{"nctId":"NCT00192231","phase":"PHASE3","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-04","conditions":"Influenza","enrollment":120},{"nctId":"NCT00192348","phase":"PHASE1","title":"A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-05","conditions":"Healthy","enrollment":120},{"nctId":"NCT00283283","phase":"PHASE2","title":"Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-11","conditions":"Influenza","enrollment":1316},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT03314662","phase":"PHASE3","title":"Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-10-17","conditions":"Influenza, Human","enrollment":1778},{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":"Influenza","enrollment":1503},{"nctId":"NCT04355806","phase":"","title":"Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-06-01","conditions":"Non Small Cell Lung Cancer, Influenza Vaccine","enrollment":160},{"nctId":"NCT03390166","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":"Influenza","enrollment":945},{"nctId":"NCT02894840","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-11","conditions":"Influenza","enrollment":340},{"nctId":"NCT02972957","phase":"PHASE4","title":"A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2017-01-30","conditions":"Influenza","enrollment":364},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT03467074","phase":"","title":"Role of Interferon-λ and Vaccine Response","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-09-01","conditions":"Vaccine Response Impaired, Allogeneic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT01430689","phase":"PHASE4","title":"Maternal Flu Vaccine Trial in Bamako, Mali","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-09-12","conditions":"Influenza","enrollment":4193},{"nctId":"NCT03095599","phase":"PHASE2, PHASE3","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2017-03-20","conditions":"Influenza, Human","enrollment":889},{"nctId":"NCT02256488","phase":"PHASE3","title":"Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-09","conditions":"Prophylaxis: Influenza","enrollment":1561},{"nctId":"NCT02935192","phase":"PHASE3","title":"Phase 3 Trial of Serbian Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Institute of Virology, Vaccines and Sera, Torlak","startDate":"2016-11-28","conditions":"Influenza","enrollment":480},{"nctId":"NCT03859141","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-02-06","conditions":"Seasonal Influenza","enrollment":2340},{"nctId":"NCT03853993","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-01-23","conditions":"Seasonal Influenza","enrollment":2380},{"nctId":"NCT02598089","phase":"PHASE1","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2015-11","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT02585700","phase":"PHASE1","title":"A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine","status":"COMPLETED","sponsor":"Institute of Virology, Vaccines and Sera, Torlak","startDate":"2015-11","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT03143101","phase":"PHASE4","title":"Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2017-05-08","conditions":"Influenza, Healthy","enrollment":200},{"nctId":"NCT01609998","phase":"PHASE1","title":"Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-06","conditions":"Influenza","enrollment":75},{"nctId":"NCT01811823","phase":"PHASE4","title":"Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2014-03-31","conditions":"Influenza, HIV, Tuberculosis","enrollment":301},{"nctId":"NCT01695733","phase":"PHASE1","title":"Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2011-09","conditions":"Neoplasms","enrollment":21},{"nctId":"NCT01356316","phase":"PHASE4","title":"Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Adimmune Corporation","startDate":"2010-08","conditions":"Influenza","enrollment":120},{"nctId":"NCT01153685","phase":"PHASE3","title":"Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-09","conditions":"Influenza","enrollment":120},{"nctId":"NCT02133781","phase":"PHASE4","title":"B-cell Immunity to Influenza (SLVP017)- Year 1, 2009","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-07","conditions":"Influenza","enrollment":51},{"nctId":"NCT03020537","phase":"PHASE4","title":"B-cell Immunity to Influenza (SLVP017)- Year 5, 2013","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-10","conditions":"Influenza","enrollment":8},{"nctId":"NCT03020498","phase":"PHASE4","title":"B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Influenza","enrollment":91},{"nctId":"NCT02141581","phase":"PHASE4","title":"Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-08","conditions":"Influenza","enrollment":86},{"nctId":"NCT03399357","phase":"","title":"Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial","status":"UNKNOWN","sponsor":"Tan Tock Seng Hospital","startDate":"2017-05-31","conditions":"Influenza Vaccine, Immune Response, Elderly","enrollment":240},{"nctId":"NCT00964821","phase":"","title":"Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-01","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":459},{"nctId":"NCT02600585","phase":"","title":"Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2015-11","conditions":"Human Influenza","enrollment":254648},{"nctId":"NCT01682369","phase":"PHASE2","title":"ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-09","conditions":"Influenza","enrollment":90},{"nctId":"NCT03022396","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Influenza","enrollment":82},{"nctId":"NCT03022422","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-09","conditions":"Influenza","enrollment":63},{"nctId":"NCT00344305","phase":"PHASE2","title":"A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2006-05-01","conditions":"Healthy","enrollment":200},{"nctId":"NCT00858611","phase":"PHASE1","title":"VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-03-03","conditions":"Influenza, Human","enrollment":51},{"nctId":"NCT00959049","phase":"PHASE3","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-09","conditions":"Influenza","enrollment":1474},{"nctId":"NCT01987349","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-09","conditions":"Influenza","enrollment":72},{"nctId":"NCT01998477","phase":"PHASE3","title":"A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-10","conditions":"Influenza","enrollment":430},{"nctId":"NCT03023176","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-09","conditions":"Influenza","enrollment":20},{"nctId":"NCT02987374","phase":"PHASE4","title":"Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-05","conditions":"Influenza","enrollment":10},{"nctId":"NCT01737710","phase":"NA","title":"Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-10","conditions":"Dermatitis, Atopic","enrollment":368},{"nctId":"NCT02214225","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-08","conditions":"Influenza, Human","enrollment":3484},{"nctId":"NCT01518478","phase":"EARLY_PHASE1","title":"Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-11","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT01246999","phase":"PHASE4","title":"Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2010-10","conditions":"Influenza","enrollment":34},{"nctId":"NCT00731393","phase":"PHASE3","title":"Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Influenza","enrollment":157},{"nctId":"NCT02710409","phase":"PHASE3","title":"A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2016-01","conditions":"Influenza","enrollment":3664},{"nctId":"NCT02806804","phase":"PHASE3","title":"Safety and Immunogenicity Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged Years 3-60","status":"UNKNOWN","sponsor":"Beijing Chaoyang District Centre for Disease Control and Prevention","startDate":"2016-05","conditions":"Quadrivalent Influenza Virus Vaccine","enrollment":2400},{"nctId":"NCT00836953","phase":"PHASE4","title":"Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2003-09","conditions":"Influenza","enrollment":33},{"nctId":"NCT01011049","phase":"PHASE2","title":"Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-09","conditions":"Influenza","enrollment":1250},{"nctId":"NCT00835926","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2003-07","conditions":"Influenza","enrollment":121},{"nctId":"NCT00772109","phase":"PHASE3","title":"Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":4292},{"nctId":"NCT01498718","phase":"PHASE1","title":"Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-12","conditions":"Influenza","enrollment":131},{"nctId":"NCT01992107","phase":"PHASE3","title":"Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Influenza","enrollment":2333},{"nctId":"NCT00645411","phase":"PHASE2, PHASE3","title":"Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Influenza","enrollment":3604},{"nctId":"NCT00976469","phase":"PHASE1, PHASE2","title":"A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2009-09","conditions":"Influenza, Pandemic Influenza","enrollment":400},{"nctId":"NCT02104869","phase":"PHASE4","title":"Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2014-04","conditions":"Human Influenza","enrollment":195},{"nctId":"NCT01240746","phase":"PHASE3","title":"Study of Quadrivalent Influenza Vaccine Among Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-11","conditions":"Influenza","enrollment":4363},{"nctId":"NCT01797029","phase":"PHASE3","title":"A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh","status":"COMPLETED","sponsor":"PATH","startDate":"2013-02","conditions":"Influenza","enrollment":1761},{"nctId":"NCT01854632","phase":"PHASE3","title":"Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal","status":"COMPLETED","sponsor":"PATH","startDate":"2013-05","conditions":"Influenza","enrollment":1761},{"nctId":"NCT01625689","phase":"PHASE2","title":"Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine","status":"COMPLETED","sponsor":"PATH Vaccine Solutions","startDate":"2012-06","conditions":"Influenza","enrollment":309},{"nctId":"NCT01712984","phase":"PHASE3","title":"Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-10","conditions":"Influenza","enrollment":3360},{"nctId":"NCT01825200","phase":"PHASE3","title":"Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2013-03","conditions":"Influenza","enrollment":2640},{"nctId":"NCT01527825","phase":"PHASE3","title":"Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2012-09","conditions":"Influenza","enrollment":800},{"nctId":"NCT01816464","phase":"PHASE4","title":"Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected Women","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2013-09","conditions":"Influenza","enrollment":150},{"nctId":"NCT00170547","phase":"PHASE2","title":"Comparison of Delivery Routes of Flu Vaccine in Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Influenza","enrollment":1597},{"nctId":"NCT00307177","phase":"PHASE2","title":"Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-08","conditions":"Influenza","enrollment":28},{"nctId":"NCT02249221","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":84},{"nctId":"NCT02121782","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2014-05","conditions":"Influenza","enrollment":84},{"nctId":"NCT02105519","phase":"PHASE4","title":"The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2013-10","conditions":"Immunogenicity and Adverse Drug Effect of Vaccines Influenza, Chronic Kidney Disease","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Trivalent influenza vaccine B","genericName":"Trivalent influenza vaccine B","companyName":"Shanghai Institute Of Biological Products","companyId":"shanghai-institute-of-biological-products","modality":"Biologic","firstApprovalDate":"","aiSummary":"This trivalent influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus (typically two A strains and one B strain). Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}